Last reviewed 2026-04-19 · How we verify

OXAMARIN

Phase 2 active Small molecule

OXAMARIN is a drug. It is currently in Phase 2 development.

OXAMARIN works by binding to a specific target, but the exact mechanism is unknown.

OXAMARIN is a small molecule drug with unknown target and drug class. Its commercial status is unclear, and it is not known whether it is FDA approved or off-patent. There is limited information available on its approved indications, half-life, and bioavailability. Further research is needed to understand its mechanism of action and key safety considerations. As a result, OXAMARIN is not widely recognized in the pharmaceutical industry.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	OXAMARIN
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells have locks on them, and OXAMARIN is a key that fits into one of those locks. When it binds, it can either unlock a beneficial process or block a harmful one, but the details of how it does this are not yet clear.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

OXAMARIN CI brief — competitive landscape report
OXAMARIN updates RSS · CI watch RSS

Frequently asked questions about OXAMARIN

What is OXAMARIN?

OXAMARIN is a Small molecule drug.

How does OXAMARIN work?

OXAMARIN works by binding to a specific target, but the exact mechanism is unknown.

What development phase is OXAMARIN in?

OXAMARIN is in Phase 2.

Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing